Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics AG (symbol: CRSP) is a pioneering gene editing company dedicated to the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. This revolutionary technology allows for precise, directed changes to genomic DNA, enabling the treatment of genetically defined diseases.
The company's portfolio spans a broad range of therapeutic programs, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. One of its notable achievements is the development and approval of Casgevy, a therapeutic targeting sickle cell disease and transfusion-dependent beta-thalassemia, developed in collaboration with Vertex Pharmaceuticals.
To bolster its research and development, CRISPR Therapeutics has forged strategic partnerships with renowned companies such as Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc. These collaborations aim to accelerate and expand the company's efforts in bringing novel therapies to market.
Headquartered in Zug, Switzerland, CRISPR Therapeutics operates through its wholly-owned U.S. subsidiary, with R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California, and London, United Kingdom.
The company's ongoing projects include advancing gene editing programs in immuno-oncology and developing stem cell-derived therapies for the treatment of Type 1 diabetes. With its innovative approach and strategic collaborations, CRISPR Therapeutics is at the forefront of the gene editing revolution, poised to make significant impacts in the field of medicine.
For more information, please visit www.crisprtx.com.
CRISPR Therapeutics (Nasdaq: CRSP) announced it received Priority Medicines designation from the European Medicines Agency for CTX001™, a gene-edited therapy for transfusion-dependent beta thalassemia (TDT). Over 30 patients have been dosed in ongoing trials, with enrollment completion expected in 2021. The company's financial results for Q1 2021 showed a net loss of $113.2 million, an increase from $69.7 million the previous year, and R&D expenses rose to $90.6 million. CRISPR also amended its agreement with Vertex for CTX001, sharing costs and profits 40/60.
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 – Vertex Pharmaceuticals and CRISPR Therapeutics announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, a CRISPR/Cas9 gene-edited therapy for transfusion-dependent beta thalassemia (TDT). This designation aims to expedite the development and evaluation of innovative therapies.
CTX001 has also received multiple FDA designations and is currently being evaluated in ongoing clinical trials for TDT and severe sickle cell disease (SCD).
Vertex Pharmaceuticals and CRISPR Therapeutics have revised their collaboration agreement for CTX001, a CRISPR/Cas9-based gene editing therapy aimed at treating sickle cell disease and beta-thalassemia. Vertex will lead the development, manufacturing, and commercialization of CTX001, responsible for 60% of program costs and profits. CRISPR will receive a $900 million upfront payment and up to $200 million upon regulatory approval. Vertex sees significant commercial potential in CTX001, having dosed over 30 patients with encouraging clinical results.
CRISPR Therapeutics (Nasdaq: CRSP) announced promising preclinical data from its allogeneic CAR-T program at the AACR Annual Meeting 2021. The study showcased that CAR-T cells with CD70 knockout displayed enhanced potency and persistence compared to conventional CAR-T cells. The research explored the effects of CRISPR/Cas9 gene editing on various checkpoint genes, revealing CD70's superior efficacy. The ongoing clinical trials of CTX130, targeting CD70-expressing tumors, expect to report top-line data in 2021, marking a significant step in cancer treatment innovation.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 9:30 a.m. ET. Members of the senior management team will represent the company.
A live webcast will be available on the company's Investors page, with a replay archived for 14 days following the event. CRISPR Therapeutics is focused on developing gene-based medicines using its proprietary CRISPR/Cas9 platform, targeting serious diseases across various fields.
CRISPR Therapeutics (Nasdaq: CRSP) will present a poster at the AACR Annual Meeting, focusing on a novel approach to augment CAR-T cell function through CD70 knockout technology. The presentation is scheduled for April 10, 2021, at 8:30 a.m. ET. This virtual event will showcase advancements in immunology and the potential of CRISPR's gene-editing platform. The company aims to develop transformative medicines for serious diseases, leveraging collaborations with industry leaders like Bayer and Vertex Pharmaceuticals.
CRISPR Therapeutics (Nasdaq: CRSP) announces its participation in two upcoming virtual investor conferences in March 2021. The Barclays Global Healthcare Conference will take place on March 9, 2021, at 10:20 a.m. ET, and the 33rd Annual Roth Conference is scheduled for March 15, 2021, at 1:30 p.m. ET. Investors can access live webcasts through the company's website, with replay available for 14 days post-event. CRISPR Therapeutics is a leader in gene editing, developing transformative medicines for serious diseases using its proprietary CRISPR/Cas9 platform.
CRISPR Therapeutics (Nasdaq: CRSP) reported its fourth quarter and full-year 2020 financial results, highlighting a net loss of $107 million for Q4 and $348.9 million for the year. Collaboration revenue dramatically decreased to $0.2 million in Q4 2020 from $77 million in Q4 2019. Research and development expenses increased to $82.4 million in Q4 2020 due to advancements in its clinical programs. More than 20 patients have been dosed in the ongoing trials of CTX001 for certain blood disorders, with expected completion in 2021, marking a pivotal year for growth.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in the Guggenheim Healthcare Talks 2021 Oncology Day on February 12, 2021, at 3:30 p.m. ET. Senior management team members will represent the company during this event. A live webcast is available on the company's Investors website, with a replay accessible for 14 days post-event. CRISPR Therapeutics focuses on developing transformative gene-based medicines utilizing its proprietary CRISPR/Cas9 technology, with initiatives across various disease areas such as oncology and hemoglobinopathies.
CRISPR Therapeutics (Nasdaq: CRSP) appointed Philippe Drouet as Chief Commercial Officer on February 1, 2021. Drouet, with over 20 years in global pharmaceutical marketing, is expected to drive the company’s commercialization efforts. His previous roles include Senior VP at Merck, where he led the launch of Keytruda, and President of Hospira’s U.S. division. The CEO emphasized Drouet's leadership will be crucial as CRISPR advances its gene-based therapies across oncology and hematology.
FAQ
What is the current stock price of Crispr Therapeut (CRSP)?
What is the market cap of Crispr Therapeut (CRSP)?
What is CRISPR Therapeutics AG?
What does the CRISPR/Cas9 platform do?
Where is CRISPR Therapeutics headquartered?
What is Casgevy?
What types of diseases is CRISPR Therapeutics targeting?
Who are CRISPR Therapeutics' key partners?
What are some of CRISPR Therapeutics' current projects?
Where are CRISPR Therapeutics' R&D operations based?
How has CRISPR Therapeutics impacted the field of medicine?
Where can I find more information about CRISPR Therapeutics?
